Daewon Pharmaceutical Co., Ltd. (KRX:003220)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,390
-40 (-0.35%)
At close: Feb 6, 2026
-21.72%
Market Cap244.13B -24.6%
Revenue (ttm)590.70B -0.5%
Net Income-16.04B
EPS-748.20
Shares Out21.43M
PE Ration/a
Forward PE32.08
Dividend300.00 (2.63%)
Ex-Dividend Daten/a
Volume43,704
Average Volume43,550
Open11,400
Previous Close11,430
Day's Range11,130 - 11,400
52-Week Range11,130 - 15,350
Beta0.20
RSI41.59
Earnings DateMar 17, 2026

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t... [Read more]

Sector Healthcare
Founded 1958
Employees 1,283
Stock Exchange Korea Stock Exchange
Ticker Symbol 003220
Full Company Profile

Financial Performance

In 2024, Daewon Pharmaceutical's revenue was 598.16 billion, an increase of 13.51% compared to the previous year's 526.95 billion. Earnings were 14.21 billion, a decrease of -40.59%.

Financial Statements